AXSM Initiates ADHD Trial
Axsome Therapeutics initiates FOCUS-3 Phase 3 trial of Solriamfetol in adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.